To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Efficacy of a cannabis-based oromucosal spray in managing peripheral neuropathic pain

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
September 2018

Efficacy of a cannabis-based oromucosal spray in managing peripheral neuropathic pain

Vol: 7| Issue: 9| Number:13| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment

Eur J Pain. 2014 Aug;18(7):999-1012. doi: 10.1002/j.1532-2149.2013.00445.x

Contributing Authors:
M Serpell S Ratcliffe J Hovorka M Schofield L Taylor H Lauder E Ehler

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

303 patients with peripheral neuropathic pain (PNP) were randomized to either Nabiximols or placebo for 14 weeks. Significant improvements in pain, quality of sleep and Subject Global Impression of Change (SGIC) were found in patients that received Nabiximols compared to those that received placebo. No patients experienced severe treatment-related adverse events in the Sativex group versus one in ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue